Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Potter, Michelle C ^a   Wozniak, Krystyna M ^a   Callizot, Noelle ^b   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Research and Development Neuro Sys SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 MERCAPTOPROPYL) PENTANEDIOIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; UNCLASSIFIED DRUG; 2-(3-MERCAPTOPROPYL)PENTANEDIOIC ACID; GLUTARIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; PROTEINASE INHIBITOR; PYRIDOXINE; THIOL DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; ELECTROMYOGRAPHY; ENZYME INHIBITION; FEMALE; HEAT SENSITIVITY; HOT PLATE TEST; LATENT PERIOD; MOTOR COORDINATION; NERVE DEGENERATION; NEUROPATHY; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PERIPHERAL NEUROPATHY; RAT; RESPONSE TIME; SENSORY NERVE CONDUCTION; SENSORY NEUROPATHY; YOUNG ADULT; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; SENSATION; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BEHAVIOR, ANIMAL; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTARATES; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; PYRIDOXINE; RATS; RATS, SPRAGUE-DAWLEY; SENSATION; SULFHYDRYL COMPOUNDS;

EID: 84907584447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102936     Document Type: Article

References (51)

1. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5: 1396-1402.
2. Neale JH (2011) N-acetylaspartylglutamate is an agonist at mGluR(3) in vivo and in vitro. J Neurochem 119: 891-895.
3. Neale JH, Bzdega T, Wroblewska B (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 75: 443-452.
4. Barinka C, Rojas C, Slusher B, Pomper M (2012) Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 19: 856-870.
5. Carpenter KJ, Sen S, Matthews EA, Flatters SL, Wozniak KM, et al. (2003) Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. Neuropeptides 37: 298-306.
6. Chen SR, Wozniak KM, Slusher BS, Pan HL (2002) Effect of 2-(phosphonomethyl)- pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 300: 662-667.
7. Yamamoto T, Hirasawa S, Wroblewska B, Grajkowska E, Zhou J, et al. (2004) Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 20: 483-494.
8. Yamada T, Zuo D, Yamamoto T, Olszewski RT, Bzdega T, et al. NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Mol Pain 8: 67.
9. Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A 100: 9554-9559.
10. Long JB, Yourick DL, Slusher BS, Robinson MB, Meyerhoff JL (2005) Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol 508: 115-122.
11. Zhong C, Zhao X, Sarva J, Kozikowski A, Neale JH, et al. (2005) NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma 22: 266-276.
12. Zhang W, Murakawa Y, Wozniak KM, Slusher B, Sima AA (2006) The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 247: 217-223.
13. Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, et al. (2010) Glutamate carboxypeptidase inhibition reduces the severity of chemotherapyinduced peripheral neurotoxicity in rat. Neurotox Res 17: 380-391.
14. Witkin JM, Gasior M, Schad C, Zapata A, Shippenberg T, et al. (2002) NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 43: 348-356.
15. Peng XQ, Li J, Gardner EL, Ashby CR, Jr., Thomas A, et al. (2010) Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaineinduced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol 627: 156-161.
16. Xi ZX, Li X, Peng XQ, Li J, Chun L, et al. (2010) Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3- mediated mechanism. J Neurochem 112: 564-576.
17. Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, et al. (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 46: 1989-1996.
18. van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, et al. (2005) The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 60: 128-136.
19. Takatsu Y, Fujita Y, Tsukamoto T, Slusher BS, Hashimoto K (2011) Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpineinduced prepulse inhibition deficits in mice. Brain Res 1371: 82-86.
20. Kozela E, Wrobel M, Kos T, Wojcikowski J, Daniel WA, et al. (2005) 2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. Psychopharmacology (Berl) 183: 275-284.
21. Majer P, Hin B, Stoermer D, Adams J, Xu W, et al. (2006) Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem 49: 2876-2885.
22. Vornov JJ, Wozniak KM, Wu Y, Rojas C, Rais R, et al. (2013) Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. J Pharmacol Exp Ther 346: 406-413.
23. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, et al. (1983) Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 309: 445-448.
24. Albin RL, Albers JW, Greenberg HS, Townsend JB, Lynn RB, et al. (1987) Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 37: 1729-1732.
25. Parry GJ, Bredesen DE (1985) Sensory neuropathy with low-dose pyridoxine. Neurology 35: 1466-1468.
26. Helgren ME, Cliffer KD, Torrento K, Cavnor C, Curtis R, et al. (1997) Neurotrophin-3 administration attenuates deficits of pyridoxine-induced largefiber sensory neuropathy. J Neurosci 17: 372-382.
27. Callizot N, Warter JM, Poindron P (2001) Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol. Neurobiol Dis 8: 626-635.
28. Ollivier-Lanvin K, Keeler BE, Siegfried R, Houle JD, Lemay MA (2010) Proprioceptive neuropathy affects normalization of the H-reflex by exercise after spinal cord injury. Exp Neurol 221: 198-205.
29. Perry TA, Weerasuriya A, Mouton PR, Holloway HW, Greig NH (2004) Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol 190: 133-144.
30. Head KA (2006) Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 11: 294-329.
31. Bosy-Westphal A, Holzapfel A, Czech N, Muller MJ (2001) Plasma folate but not vitamin B(12) or homocysteine concentrations are reduced after short-term vitamin B(6) supplementation. Ann Nutr Metab 45: 255-258.
32. Jortner BS (2000) Mechanisms of toxic injury in the peripheral nervous system: neuropathologic considerations. Toxicol Pathol 28: 54-69.
33. Kobayashi C, Kurohane K, Imai Y (2012) High dose dietary pyridoxine induces T-helper type 1 polarization and decreases contact hypersensitivity response to fluorescein isothiocyanate in mice. Biol Pharm Bull 35: 532-538.
34. Hernandez TD, Schallert T (1988) Seizures and recovery from experimental brain damage. Exp Neurol 102: 318-324.
35. Carozzi VA, Canta A, Oggioni N, Ceresa C, Marmiroli P, et al. (2008) Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. J Anat 213: 539-546.
36. Bacich DJ, Wozniak KM, Lu XC, O'Keefe DS, Callizot N, et al. (2005) Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem 95: 314-323.
37. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, et al. (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 18: 9594-9600.
38. Wroblewska B,Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, et al. (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69: 174-181.
39. Berent-Spillson A, Robinson AM, Golovoy D, Slusher B, Rojas C, et al. (2004) Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. J Neurochem 89: 90-99.
40. Thomas AG, Bodner A, Ghadge G, Roos RP, Slusher BS (2009) GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. J Neurovirol 15: 449-457.
41. Bergeron R, Coyle JT (2012) NAAG, NMDA receptor and psychosis. Curr Med Chem 19: 1360-1364.
42. Losi G, Vicini S, Neale J (2004) NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 46: 490-496.
43. Fricker AC, Mok MH, de la Flor R, Shah AJ, Woolley M, et al. (2009) Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 56: 1060-1067.
44. Zhang W, Slusher B, Murakawa Y, Wozniak KM, Tsukamoto T, et al. (2002) GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 194: 21-28.
45. Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1: 101-110.
46. Urazaev AK, Buttram JG Jr, Deen JP, Gafurov BS, Slusher BS, et al. (2001) Mechanisms for clearance of released N-acetylaspartylglutamate in crayfish nerve fibers: implications for axon-glia signaling. Neuroscience 107: 697-703.
47. Adedoyin MO, Vicini S, Neale JH (2010) Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain 6: 60.
48. Cliffer KD, Tonra JR, Carson SR, Radley HE, Cavnor C, et al. (1998) Consistent repeated M- and H-Wave recording in the hind limb of rats. Muscle Nerve 21: 1405-1413.
49. Arkaravichien T, Sattayasai N, Daduang S, Sattayasai J (2003) Dose-dependent effects of glutamate in pyridoxine-induced neuropathy. Food Chem Toxicol 41: 1375-1380.
50. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, et al. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxineinduced peripheral sensory neuropathy. Exp Neurol 203: 293-301.
51. Chattopadhyay M, Goss J, Lacomis D, Goins WC, Glorioso JC, et al. (2003) Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci 17: 732-740.